Funding decisions on applications are made following a rigorous peer review. Peer review is a way of assessing the quality of scientific ideas. Our processes meet the Association of Medical Research Charities five principles of peer review.
Funding decisions on Strategic Research Centre (SRC) applications are made following a rigorous peer review by external scientists and clinicians before being considered by our Strategy Implementation Board (SIB), which recommends applications for funding.
We agree Venture and Innovation Award (VIA) funding in principle prior to submission of external funding body applications. The VIA programme relies on the science being peer reviewed by the external funding body. This means we can only consider applications where this peer review will take place. For industry awards, we request evidence of internal review prior to awarding funding.
Summer studentships are not subjected to external peer review.
Recommendations for funding will be judged on how well applications meet the five principles that guide our approach – our 'SCORE' objectives:
- Strategic – We will lead on the basis of clear priorities, actions and goals.
- Collaborative – We will leverage income and attract other funding agencies to work in partnership to maximise funding opportunities.
- Outcome-focused – We will be mission-driven, strategic in allocating resources, and results-oriented.
- Risk-based – We will pursue a balanced and diverse portfolio of research of varying risks: high risk vs lower risk and basic vs applied science, that benefits all people with cystic fibrosis.
- Excellence-driven – We will be driven by quality and harness expertise wherever we find it.
Our Strategic Implementation Board
Our Strategic Implementation Board (SIB) is an independent committee that reports to the Board of Trustees, making recommendations and providing guidance regarding the implementation of the Trust’s research strategy. This includes making recommendations for funding and reviewing progress of ongoing grants.
Members of SIB are invited from a range of backgrounds including biomedical lab-based science, clinicians and representatives of the CF community.